Evidence map›Paper›PMID 33864468›Full record

ArticleThe Journal of clinical endocrinology and metabolism2021

Soluble Alpha Klotho in Acromegaly: Comparison With Traditional Markers of Disease Activity.

Júnia R O L Schweizer, Katharina Schilbach, Michael Haenelt, Alexandre V Giannetti, Mariana F Bizzi, Beatriz S Soares, Eduardo Paulino, Jochen Schopohl, Sylvère Störmann, Antônio Ribeiro-Oliveira and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Acromegaly diagnosis.The Journal of clinical endocrinology and metabolism · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Júnia R O L SchweizerEndocrine Research Unit, Medizinische Klinik und Poliklinik IV, LMU Klinikum, Munich, Germany.
Katharina SchilbachEndocrine Research Unit, Medizinische Klinik und Poliklinik IV, LMU Klinikum, Munich, Germany.
Michael HaeneltEndocrine Research Unit, Medizinische Klinik und Poliklinik IV, LMU Klinikum, Munich, Germany.
Alexandre V GiannettiSurgery Department-Federal University of Minas Gerais, Belo Horizonte, Brazil.
Mariana F BizziEndocrine Laboratory-Federal University of Minas Gerais, Belo Horizonte, Brazil.
Beatriz S SoaresEndocrine Laboratory-Federal University of Minas Gerais, Belo Horizonte, Brazil.
Eduardo PaulinoPathology Department-Federal University of Minas Gerais, Belo Horizonte, Brazil.
Jochen SchopohlEndocrine Research Unit, Medizinische Klinik und Poliklinik IV, LMU Klinikum, Munich, Germany.
Sylvère StörmannEndocrine Research Unit, Medizinische Klinik und Poliklinik IV, LMU Klinikum, Munich, Germany.
Antônio Ribeiro-OliveiraEndocrine Laboratory-Federal University of Minas Gerais, Belo Horizonte, Brazil.
Martin BidlingmaierEndocrine Research Unit, Medizinische Klinik und Poliklinik IV, LMU Klinikum, Munich, Germany.ORCID 0000-0002-4681-6668
LMU Klinikum · DEUniversidade Federal de Minas Gerais · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextSoluble alpha klotho (sαKL) has been linked to growth hormone (GH) action, but systematic evaluation and comparisons with traditional biomarkers in acromegaly are lacking.

objectiveTo evaluate the potential of sαKL to aid classification of disease activity.

methodsThis retrospective study at 2 academic centers included acromegaly patients before surgery (A, n = 29); after surgery (controlled, discordant, or uncontrolled) without (B1, B2, B3, n = 28, 11, 8); or with somatostatin analogue treatment (C1, C2, C3, n = 17, 11, 5); nonfunctioning pituitary adenomas (n = 20); and healthy controls (n = 31). sαKL was measured by immunoassay and compared with traditional biomarkers (random and nadir GH, insulin-like growth factor I [IGF-I], IGF binding protein 3). Associations with disease activity were assessed.

resultssαKL was correlated to traditional biomarkers, particularly IGF-I (rs=0.80, P <0.0001). High concentrations before treatment (A, median, interquartile range: 4.04 × upper limit of normal [2.26-8.08]) dropped to normal after treatment in controlled and in most discordant patients. A cutoff of 1548 pg/mL for sαKL discriminated controlled (B1, C1) and uncontrolled (B3, C3) patients with 97.8% (88.4%-99.9%) sensitivity and 100% (77.1%-100%) specificity. sαKL was below the cutoff in 84% of the discordant subjects. In the remaining 16%, elevated sαKL and IGF-I persisted, despite normal random GH. Sex, age, body mass index, and markers of bone and calcium metabolism did not significantly affect sαKL concentrations.

conclusionOur data support sαKL as a biomarker to assess disease activity in acromegaly. sαKL exhibits close association with GH secretory status, large dynamic range, and robustness toward biological confounders. Its measurement could be helpful particularly when GH and IGF-I provide discrepant information.

Indexed as

AcromegalyAdenomaAdultAgedAged, 80 and overBiomarkersFemaleGlucuronidaseHuman Growth HormoneHumansInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IKlotho ProteinsMaleMiddle AgedPituitary NeoplasmsBiomarkersGlucuronidaseHuman Growth HormoneIGFBP3 protein, humanInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IKlotho Proteinsbiomarkersdiscordantgrowth hormoneinsulin-like growth factor-binding protein 3insulin-like growth factor I

Identifiers

PMID33864468
PMCPMC8277223
OpenAlexW3154733021

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.